Skip links

After a new cancer drug is approved for adults, pediatric clinical research takes an average of 9.5 more years.
After a new cancer drug is approved for adults, pediatric clinical research takes an average of 9.5 more years.
In the past 25 YEARS, the FDA has initially approved only THREE DRUGS for a childhood cancer.
In the past 25 YEARS, the FDA has initially approved only THREE DRUGS for a childhood cancer.
Number of cancer drugs in the pipeline for adults: 900.  For kids: ALMOST NONE.
Number of cancer drugs in the pipeline for adults: 900. For kids: ALMOST NONE.

WHAT IF

we focused as much effort on solving cancer for children as we do on solving cancer for adults?

How we are advancing our mission

 

The Creating Hope Act

CREATING HOPE ACT PEDIATRIC PRV

WHAT IF there were drugs specially developed for children with life threatening illnesses?
MORE »

 

The Kids Act/RACE for Children Act

RACE FOR CHILDREN ACT

WHAT IF drugs developed for adults with cancer were also developed for kids?
MORE »

 

Compassionate Use Navigator

COMPASSIONATE USE NAVIGATOR

WHAT IF we could save a child by helping obtain an investigational drug?
MORE »

 

Tissue Donation

TISSUE DONATION

WHAT IF we could help pediatric cancer investigators get the tissue they need to succeed in their research?
MORE »

 

News

Be Part of GivingTuesday

We are changing the landscape of pediatric cancer research The Creating Hope Act has generated almost $1 billion in R&D incentives for pediatric cancer drugs. Our Compassionate Use read more →

News

What you can do today

Share Your Story

Your story raises awareness about the need for pediatric cancer research. Please read stories of other kids.
Share your story here»

Youth Lobby Days

Join our Youth Lobby Days in Washington, D.C. and tell Congress what you think about pediatric cancer.  Sign-up here

Donate

Please make your donation today. Your support makes our work possible. Thank you!

Recognition of our work

We  have created almost $1 billion in R&D incentives for pediatric rare disease drug development.